Ignite Creation Date:
2024-05-06 @ 3:46 PM
Last Modification Date:
2024-10-26 @ 1:56 PM
Study NCT ID:
NCT04747197
Status:
COMPLETED
Last Update Posted:
2023-07-19
First Post:
2021-02-06
Brief Title:
First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration wAMD
Sponsor:
EyePoint Pharmaceuticals Inc
Organization:
EyePoint Pharmaceuticals Inc
Study Overview
Official Title:
A Phase 1 Multicenter Prospective Open-Label Dose Escalation Study of EYP-1901 a Tyrosine Kinase Inhibitor TKI in Subjects With Wet AMD
Status:
COMPLETED
Status Verified Date:
2023-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase 1 open-label study to assess the bioactivity ocular and systemic safety tolerability and pharmacokinetics of a single dose injections of EYP-1901 at three dose levels 440 µg 2060 µg and 3090 µg in subjects with Wet Age Related Macular Degeneration wAMD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None